A5048279797- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Systemic Lupus Erythematosus Research
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Optic Conditions
- Polyomavirus and related diseases
- Ophthalmology and Eye Disorders
- T-cell and Retrovirus Studies
- SARS-CoV-2 and COVID-19 Research
- CNS Lymphoma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Otitis Media and Relapsing Polychondritis
- Vasculitis and related conditions
- Rheumatoid Arthritis Research and Therapies
- Health, Nursing, Elderly Care
- Infectious Diseases and Tuberculosis
- Leprosy Research and Treatment
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Glioma Diagnosis and Treatment
- Mosquito-borne diseases and control
- IgG4-Related and Inflammatory Diseases
- Syphilis Diagnosis and Treatment
- Science and Science Education
- Drug-Induced Ocular Toxicity
Universidade Federal de Minas Gerais
2015-2025
Charité - Universitätsmedizin Berlin
2015-2023
Universidade do Estado de Minas Gerais
2021-2023
Inserm
2023
Centre National de la Recherche Scientifique
2023
Centre de Recherche en Neurosciences de Lyon
2023
Hospital das Clínicas da Universidade Federal de Minas Gerais
2021
Humboldt-Universität zu Berlin
2021
Freie Universität Berlin
2021
Max Delbrück Center
2021
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or extensive may occur. The International Panel for Diagnosis (IPND) was convened to develop revised using systematic literature reviews electronic surveys facilitate consensus. new nomenclature defines the unifying term...
To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) or seronegativity for both antibodies.Sera from diagnosed NMOSD in 1 of 3 centers (2 sites Brazil and site Japan) were tested MOG AQP4 antibodies using cell-based assays live transfected cells.Among the 215 NMOSD, 7.4% (16/215) positive 64.7% (139/215) antibodies. No Patients represented 21.1% (16/76) negative...
Objective: To describe 16 patients with a coincidence of 2 rare diseases: aquaporin-4 antibody (AQP4-Ab)–mediated neuromyelitis optica spectrum disorder (AQP4-NMOSD) and acetylcholine receptor (AChR-Ab)–mediated myasthenia gravis (AChR-MG). Methods: The clinical details results AChR-MG AQP4-NMOSD were analyzed retrospectively. Results: All had early-onset AChR-MG, the majority mild generalized disease, high proportion achieved remission. Fifteen female; 11 Caucasian. In 14/16, MG preceded...
To determine optic nerve and retinal damage in aquaporin-4 antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorders (NMOSD) a large international cohort after previous studies have been limited by small heterogeneous cohorts.The cross-sectional Collaborative Retrospective Study on optical coherence tomography (OCT) collected retrospective data from 22 centers. Of 653 screened participants, we included 283 AQP4-IgG-seropositive patients with NMOSD 72 healthy controls (HCs)....
<h3>Background and Objectives</h3> Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)–seropositive NMOSD (eculizumab, inebilizumab, satralizumab), prompting need to consider best practice therapeutic decision-making this indication. Our objective was develop validated statements management AQP4-IgG–seropositive NMOSD,...
PURPOSE: To develop and investigate the reliability validity of a Brazilian version 25-Item National Eye Institute Visual Function Questionnaire. METHODS: A questionnaire was developed applied to patients with chronic eye diseases healthy controls. Reliability assessed by Cronbach's alpha coefficient, intraclass correlation coefficient interrater coefficient. Participants were submitted Medical Outcomes Study Short Form-36 Validity estimated between questionnaires among 12 subscales...
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from Brazilian Committee on Treatment Research Multiple Sclerosis Neuroimmunology Scientific Department Academy Neurology have convened to establish Consensus MS, based their understanding that neurologists should be able prescribe MS DMTs...
Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment high-dose corticosteroids for ON is based on a North American study population, which did not address timing or antibody serostatus. Acute Neuritis Network (ACON) presents global, prospective, observational protocol primarily designed to investigate effect...
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) is an increasing diagnostic and therapeutic challenge in Latin America (LATAM). Despite the heterogeneity of this population, ethnic socioeconomic commonalities exist, epidemiologic studies from region have had a limited geographic population outreach. Identification some aspects entire are lacking.ObjectivesTo determine ethnic, clinical characteristics, utilization tools types therapy for patients with NMOSD American...
Background The novel optic neuritis (ON) diagnostic criteria include intereye differences (IED) of optical coherence tomography (OCT) parameters. IED has proven valuable for ON diagnosis in multiple sclerosis but not been evaluated aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD). We the accuracy absolute (IEAD) and percentage difference (IEPD) AQP4+NMOSD after unilateral >6 months before OCT as compared with healthy controls (HC). Methods...
The discovery of aquaporin 4 immunoglobulin G (AQP4-IgG) autoantibody, present in ∼80% patients with neuromyelitis optica spectrum disorder (NMOSD), dramatically improved its diagnosis, treatment, and prognosis. While Brazil has a higher prevalence NMOSD (up to 4.5 per 100,000 people) compared global averages, disparities access testing impede early diagnosis treatment. To tackle these issues, the Americas Health Foundation convened three-day virtual conference six Brazilian experts. This...
Investigations on the prevalence rates of multiple sclerosis (MS) around world have yielded important clues interplay between genetic susceptibility and environmental factors. As Brazil is a huge country laid many latitudes inhabited by population with distinct ethnic backgrounds, it might be assumed that frequency MS varies in its different regions. Objective: To determine rate Belo Horizonte, capital State Minas Gerais, Southeastern Brazil. Methods: We used six sources to draw up...